George A, et al. - Researchers assessed invasive and in situ breast cancer risk among Women's Health Initiative participants (N = 155,737) in relation to psychotropic medication use (any, typical antipsychotics, atypical antipsychotics, and lithium), by estimating hazard ratios and 95% confidence intervals. They noted a low prevalence of psychotropic medication use (n = 642; 0.4%). They also reported 10,067 invasive and 2,285 in situ breast tissues diagnosed during an average 14.8 years of follow-up. A link of psychotropic medication use with invasive breast cancer risk was not supported. Variations in screening mammography utilization did not explain the likely rise in in situ breast cancer risk related to “typical” antipsychotics.